Objective To determine the clinical efficacy of flupentixol/melitracen tablets (deanxit tablets) on chronic obstructive pulmonary disease(COPD) patients accompanied with depression and anxiety symptoms. Methods A total of 128 COPD patients with symptoms of anxiety and/or depression in our department from January 2018 to January 2019 were recruited in this study. They were divided into the deanxit group and control group. The patients of the control group only received conventional COPD treatment, while those of the treatment group were given oral administration of deanxit in every morning besides conventional treatment for COPD. After 4 weeks, Hamilton anxiety scale (HAMA), Hamilton depression scale (HAMD), clinical symptoms and modified British medical research council scale (mMRC) were used to survey their mental and physical conditions before and after treatment. Pulmonary function parameters, such as forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1 as a percentage of predicted value (FEV1% pred), and ratio of FEV1 to FVC (FEV1/FVC) were also measured. The results were compared before and after treatment, and between the 2 groups. SPSS statistics 19.0 was used to perform the statistical analysis. Student′s t test or Chi-square test was employed for comparison between the groups in different data types. Results Among 128 patients, 47 patients had anxiety and depression, 57 patients had anxiety alone and 24 patients had depression alone. Compared with the control group, the deanxit group had significantly lower HAMA score [(6.1±1.3) vs (10.7±1.9)], HAMD score [(7.6±1.7) vs (9.7±2.0)], clinical symptoms score [(3.2±1.3) vs (6.0±1.7)] and mMRC score [(1.1±0.7) vs (1.9±0.4)], but obviously higher FEV1/FVC [(78.3±3.9)% vs (67.9±4.4)%] (all P<0.05). Conclusion Deanxit effectively relieves anxiety and depression symptoms and improves the quality of life in the COPD patients.